Last reviewed 2026-04-19 · How we verify

ACEDIASULFONE

Phase 2 active Small molecule

ACEDIASULFONE is a acediasulfone drug. It is currently in Phase 2 development.

Acediasulfone works by binding to a specific target, but the exact mechanism is not well understood.

Acediasulfone is a small molecule drug in the acediasulfone class, but its original developer and current owner are unknown. Its target and approved indications are also not specified. The commercial status of acediasulfone is unclear, and it is unknown whether it is patented or available as a generic medication. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also lacking. As a result, key safety considerations and potential side effects are not well established.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ACEDIASULFONE
Drug class	acediasulfone
Target	6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase, Aldose reductase, Dihydropteroate synthetase, putative
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and acediasulfone is a key that fits into those locks. When it binds, it can either unlock or block the normal functioning of the cell, depending on the specific target. This can help to treat certain diseases by either activating or inhibiting the cell's normal processes.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACEDIASULFONE CI brief — competitive landscape report
ACEDIASULFONE updates RSS · CI watch RSS

Frequently asked questions about ACEDIASULFONE

What is ACEDIASULFONE?

ACEDIASULFONE is a acediasulfone drug.

How does ACEDIASULFONE work?

Acediasulfone works by binding to a specific target, but the exact mechanism is not well understood.

What drug class is ACEDIASULFONE in?

ACEDIASULFONE belongs to the acediasulfone class. See all acediasulfone drugs at /class/acediasulfone.

What development phase is ACEDIASULFONE in?

ACEDIASULFONE is in Phase 2.

What does ACEDIASULFONE target?

ACEDIASULFONE targets 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase, Aldose reductase, Dihydropteroate synthetase, putative and is a acediasulfone.

Drug class: All acediasulfone drugs
Target: All drugs targeting 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase, Aldose reductase, Dihydropteroate synthetase, putative
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing